Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

ANCA Associated Vasculitis Clinical Trial

— VASC-FAS  

Official title:

Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03698071
• Other study ID #: CHUBX 2018/22
• Status: Recruiting
• Phase: N/A
• Start date: December 14, 2018
• Est. completion date: December 2024

Study information

• Verified date: April 2024
• Source: University Hospital, Bordeaux
• Contact: Patrick BLANCO, Prof
• Phone: (0)5 56 79 56 45
• Email: patrick.blanco[@]chu-bordeaux.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.

Description:

ANCA associated vasculitis are a rare group of diseases and potentially life-threatening inflammatory conditions. There is an urgent need to describe prognostic factors and to discover new therapeutic pathways. Soluble CD95-L is a cleaved part of CD95-L which binds the CD95 Death receptor. s-CD95-L has pro-inflammatory properties for Th17 lymphocytes and Neutrophils, two cells implicated in ANCA associated vasculitis. It also plays a role in systemic lupus erythematosus (which present with the same type of renal glomerulonephritis as ANCA-associated vasculitis). Finally, it has already be found elevated in this group of diseases. The investigators hypothesized that s-CD95-L levels might be a prognostic factor in ANCA associated vasculitis and the study of the molecular mechanisms involved could provide new therapeutic targets.

The study will recruit 50 patients with ANCA associated vasculitis followed in Bordeaux University Hospital. Among classical disease activity information, blood and urine samples will be collected at each visit to study s-CD95-L. Fundamental research will be realized on patients' sample to study molecular mechanisms involved.

Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, as their usual follow-up would request. No extra visit will be needed and blood samples will be drawn at the same time as those drawn for clinical purposes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of ANCA associated vasculitis according to the Chapel-Hill Consensus Conference - 2012 modified version

• Age = 18 years

• being affiliated to health insurance

• willing to participate and to sign informed consent.

Exclusion Criteria:

• Pregnant or breastfeeding women,

• patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)

Related Conditions & MeSH terms

• ANCA Associated Vasculitis
• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
• Vasculitis

Intervention

Biological:
• blood sample
30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
• urine sample
6 ml

Locations

Country	Name	City	State
France	CHU de Bordeaux - Service d'Immunologie et Immunogénétique	Bordeaux

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Bordeaux	National Research Agency, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of quantitative levels of s-CD95-L in ANCA associated vasculitis between baseline and Month 12		At baseline (Day 0) and 12 months from baseline
Secondary	Change of disease activity scores for ANCA associated vasculitis between baseline and Month 12	Birmingham Vasculitis Activity Score - Version 3 (BVAS 3.0) The Birmingham Vasculitis Activity Score (BVAS) is a method for assessing the activity of vasculitis. Note that scoring ranges are higher when any of the features are new or worse. Creatinine levels can be scored at patient's first assessment only. The maximum score is 63 points for present symptoms and 32 points for new symptoms or symptoms which had worsened within the previous weeks.	At baseline (Day 0) and 12 months from baseline
Secondary	Change of disease activity scores for ANCA associated vasculitis between baseline and Month 12	Vasculitis Damage Index (VDI)	At baseline (Day 0) and 12 months from baseline
Secondary	Change of quantification of s-CD95-L in the blood and urine samples of ANCA associated vasculitis between baseline and Month 12		At baseline (Day 0) and 12 months from baseline
Secondary	Change of quantification of ANCA in the blood samples of ANCA associated vasculitis between baseline and Month 12		At baseline (Day 0) and 12 months from baseline